Compare Medpace Holdings Inc (MEDP) vs Weyerhaeuser Company Common Stock (WY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Weyerhaeuser Company Common Stock — how do they compare? Medpace Holdings Inc trades at $616.98 (market cap $17.02B), while Weyerhaeuser Company Common Stock trades at $19.02 (market cap $13.67B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Weyerhaeuser Company Common Stock pays a 4.43% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | WY | |
|---|---|---|
Market Cap | $17.02B | $13.67B |
Volume | 155,250 | 6,820,453 |
Sector | Health | Real Estate |
52-Week High | $630.19 | $27.10 |
52-Week Low | $393.42 | $18.47 |
Typical Hold Time | 14 Days | — |
Enterprise Value | $16.63B | $18.59B |
Dividend Yield | — | 4.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $609.89, down 1.64% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent news highlights CEO stock sales and institutional position adjustments, while Q3 2026 results are expected October 21, 2026.
MEDP offers growth potential with a consensus price target of $620.44 (1.7% upside), supported by projected 2026 revenue growth to $2.8B. Risks include high valuation multiples (P/E 35.82) and insider selling. Analyst sentiment is cautious with 78.95% hold ratings, suggesting limited near-term catalysts.
Weyerhaeuser (WY) trades at $18.97, up 0.16% with neutral technical signals. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, while fundamentals reveal modest profitability with 6.89% net margin and 4.97% ROE. Recent news highlights institutional accumulation and upcoming Q3 earnings on October 29. The company maintains stable revenue at $6.9B but faces cash flow challenges with negative net cash flow of $203M in 2025.
Weyerhaeuser presents a mixed outlook with analyst consensus favoring bullish sentiment (52% buy ratings) and a $29.33 price target suggesting 55% upside. However, risks include weak dividend coverage, high leverage at 5x, and sensitivity to interest rates and housing market cycles. The stock's current proximity to 52-week lows offers potential value but requires careful monitoring of lumber demand recovery and Q3 earnings results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Weyerhaeuser Company Common Stock
Weyerhaeuser Company is a timberland-focused real estate investment trust (REIT) that owns and manages more than 10 million acres of timberland in US, in addition to timberlands under long-term license in Canada. The company also manufactures wood products, including lumber, oriented strand board, and engineered wood.
Read more on WY →
